Experimental vaccine triggers broadly neutralizing HIV antibodies in macaques
Researchers have reached a significant milestone in the quest for a universal HIV vaccine. Scientists at Scripps Research and Sweden’s Karolinska Institute have developed an experimental vaccine that successfully produced broadly protective antibodies in every rhesus macaque tested.
The findings, published in Nature on April 29, 2026, represent the first time that vaccination alone has consistently achieved this outcome. This development brings the scientific community closer to a vaccine capable of addressing the vast diversity of HIV strains found worldwide.
The Challenge of a Mutating Virus
HIV is characterized by its ability to mutate rapidly, often moving faster than the human immune system can react. By the time the body develops antibodies for one strain, the virus has typically mutated to evade those defenses.
A small number of people living with HIV naturally develop broadly neutralizing antibodies (bnAbs). These proteins can block multiple strains because they recognize parts of the virus that do not change, though replicating this response via a vaccine has historically been difficult.
Targeting the Viral Apex
The new vaccine focuses on the apex, or the tip, of the virus’s outer spike protein. This specific region is the only part of HIV exposed on its surface and is responsible for interacting with human cells.
Because the apex remains nearly identical across hundreds of thousands of circulating strains, it is a highly desirable target. Researchers screened a library of stabilized spike proteins to identify those capable of activating the rare immune cells that produce apex-targeting antibodies.
Proven Results in Primate Testing
In a study involving six non-human primates, the team utilized a series of vaccines. This process began with a priming candidate and followed with boosts using spike proteins from other HIV strains.
All six animals developed apex-targeted cross-neutralizing antibodies. Electron microscopy confirmed these antibodies bound to the spike’s apex in the same manner as bnAbs found in humans living with HIV.
The animals demonstrated activity against genetically distinct HIV strains they had never encountered. This capability, known as tier-2 cross-neutralization, is considered the gold standard in the field of HIV research.
The Path Toward Human Application
While the results are promising, the experimental vaccines are not yet ready for human testing. Manufacturing clinical-grade nanoparticles is currently both costly and technically demanding.
As a possible next step, the team is exploring alternative delivery methods for spike proteins, which may include the use of mRNA vaccines. This could potentially streamline the process of eliciting the required immune response.
Experts suggest that a fully protective vaccine is likely to require a multi-pronged approach. Future iterations may need to target the apex and other vulnerable sites, such as the CD4 binding site, simultaneously to ensure maximum efficacy.
Frequently Asked Questions
What part of the HIV virus does this new vaccine target? The vaccine targets the apex, or the tip, of the HIV outer spike protein (Env trimer), a region that rarely changes between different strains of the virus. Was this vaccine tested on humans? No, the current findings are based on tests conducted on six rhesus macaques. The vaccine is not yet ready for human testing due to the high cost and technical demands of manufacturing clinical-grade nanoparticles. What is tier-2 cross-neutralization? Tier-2 cross-neutralization is a benchmark in HIV research where the antibodies produced by a vaccine show activity against “wild” HIV strains that were not included in the vaccine itself. How do you think this breakthrough could change the global approach to HIV prevention?